LAURA PURKS: Open Payments
NPI 1528626322 · DURHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,946 in 99 payments from 15 companies in 2025. Trend: 2023 $1,076 · 2024 $1,874 · 2025 $1,946
Food & beverage: $1,946
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $541 |
| Otsuka America Pharmaceutical, Inc. | 19 | $287 |
| Vanda Pharmaceuticals Inc. | 16 | $282 |
| E.R. Squibb & Sons, L.L.C. | 7 | $222 |
| Alkermes, Inc. | 9 | $181 |
| Neurocrine BioSciences, Inc. | 3 | $70 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Axsome Therapeutics, Inc. | 4 | $61 |
| Collegium Pharmaceutical, Inc. | 3 | $52 |
| Noven Therapeutics, LLC | 2 | $39 |
Products named: VRAYLAR, REXULTI, COBENFY, FANAPT, HETLIOZ, ARISTADA, INGREZZA, CAPLYTA.
Industry payments across NC — which companies pay providers there.
